Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Combimatrix Corp (CBMX)

Combimatrix Corp (CBMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Combimatrix Corp 310 Goddard Suite 150 Irvine CA 92618 USA

www.combimatrix.com P: 949-753-0624

Description:

CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in potential markets where their products and services can be utilized. The Company's products and services are specially utilized in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets. The technologies they have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs.

Key Statistics

Overview:

Market Capitalization, $K 18,375
Shares Outstanding, K 2,940
Annual Sales, $ 12,870 K
Annual Net Income, $ -4,140 K
Last Quarter Sales, $ 4,010 K
Last Quarter Net Income, $ -610 K
60-Month Beta 0.86
% of Insider Shareholders 2.10%
% of Institutional Shareholders 12.78%

Growth:

1-Year Return 184.09%
3-Year Return -72.22%
5-Year Return -82.64%
5-Year Revenue Growth 182.24%
5-Year Earnings Growth -97.27%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 11/08/17
Earnings Per Share ttm -0.62
EPS Growth vs. Prev Qtr 38.46%
EPS Growth vs. Prev Year 78.95%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 02/01/16

CBMX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -27.90%
Return-on-Assets % -20.57%
Profit Margin % -32.17%
Debt/Equity 0.01
Price/Sales 1.48
Price/Cash Flow N/A
Price/Book 3.62
Book Value/Share 1.73
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar